The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
Status:
Terminated
Trial end date:
2020-11-05
Target enrollment:
Participant gender:
Summary
This is a Phase Ib study to look at the combination of an antibody immunization vaccine
strategy using oregovomab and an investigational stage immune booster (poly ICLC / Hiltonol),
both of which have previously been used in combination with other cancer treatments and
demonstrated to be active in advanced cancer, but which have not previously been used
together. This study will assess the approach as to whether these two drugs can safely add to
the response seen with either drug alone, both of which have doses that are based on prior
studies.
Subjects with stable disease for whom a 12 week break from therapy for their persistent and
progressive advanced ovarian cancer is appropriate, who have signed informed consent and for
whom baseline clinical information is completed, will receive 4 cycles of oregovomab/Hiltonol
immunization every three weeks (weeks 0, 3, 6, and 9). Blood will be obtained for to look for
a CA125 specific T cell response at 12 weeks before initiating any additional therapy
according to the best clinical judgment of the investigator. At week 16 the subjects will
receive a final dose of the combination of oregovomab/Hiltonol and at week 17 will have an
additional blood draw for analysis of T-cell response.